Chemical Formula: C17H25Cl2F3N5O12P3S2
Chemical Formula C17H25Cl2F3N5O12P3S2
Found 2 metabolite its formula value is C17H25Cl2F3N5O12P3S2
Cangrelor
C17H25Cl2F3N5O12P3S2 (774.9483)
Cangrelor (trade name: Kengreal (US), Kengrexal (Europe)) is a P2Y12 antagonist FDA approved as an antiplatelet drug that is administered intravenously to reduce ischemic events (i.e. restricted blood flow) in patients undergoing percutaneous coronary intervention (PCI). PCI, also known as coronary angioplasty, is a nonsurgical procedure which opens blocked or narrowed coronary arteries that are clogged due to a buildup of plaque. Being an adenosine triphosphate (ATP) analogue, cangrelor is able to bind the adenosine diphosphate (ADP) receptor P2Y12 and inhibit ADP-mediated platelet activation and aggregation. An advantage cangrelor provides over oral P2Y12 inhibitors (e.g. clopidogrel, ticagrelor, ticlopidine, and prasugrel) is that it is an active drug not requiring hepatic conversion, therefore, providing a rapid onset and offset of action (PMID: 27729681). B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
Cangrelor
C17H25Cl2F3N5O12P3S2 (774.9483)
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
